sar408701
mAbexperimentalADC
Clinical trial activity
12 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
10
Phase 3
1
Phase 4
0
Earliest trial started Jul 23, 2014 (NCT02187848)
Timeline
Indications
Mechanism of action
Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent
CEACAM5 inhibitor
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- maytansinoid
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298098 ↗
Also known as
- sar408701
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07287995 | Phase 1/Phase 2 (Phase 2) | Dec 15, 2025 | Astellas |
| NCT05849246 | Phase 2 | May 30, 2023 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05703555 | Phase 2 | Feb 28, 2023 | Erasmus University Rotterdam, Sanofi |
| NCT05429762 | Phase 1 | Oct 3, 2022 | Sanofi |
| NCT05245071 | Phase 2 | Jun 3, 2022 | Sanofi |
| NCT05071053 | Phase 2 | Oct 11, 2021 | Sanofi |
| NCT04659603 | Phase 2 | Mar 29, 2021 | Sanofi |
| NCT04524689 | Phase 2 | Oct 26, 2020 | Sanofi |
| NCT04394624 | Phase 2 | Jun 5, 2020 | Sanofi |
| NCT04154956 | Phase 3 | Nov 26, 2019 | Sanofi |
| NCT03324113 | Phase 1 | Oct 17, 2017 | Sanofi |
| NCT02187848 | Phase 1/Phase 2 (Phase 2) | Jul 23, 2014 | Sanofi |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 10 | 9 | 3 | 2014 |
| Astellas | For profit | 1 | 1 | 1 | 2025 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1